1. Home
  2. URGN

URGN

UroGen Pharma Ltd.

Logo UroGen Pharma Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Founded: 2004 Country:
United States
United States
Employees: N/A City: RA'ANANA
Market Cap: 515.2M IPO Year: 2017
Target Price: $35.33 AVG Volume (30 days): 354.6K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.55 EPS Growth: N/A
52 Week Low/High: $8.69 - $24.13 Next Earning Date: 05-09-2024
Revenue: $82,713,000 Revenue Growth: 28.52%
Revenue Growth (this year): 22.46% Revenue Growth (next year): 87.35%

Share on Social Networks: